Citable filing context
GILD's research view summarizes recent SEC filing context, starting with earnings from Aug 4, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 4, 2026 | earnings | Gilead Sciences reported Q2 2026 revenue of $7.8 billion and a diluted loss per share of $(8.45). |
| May 20, 2026 | debt_offering | Gilead Sciences issued $3.0 billion in 4.250%, 4.400%, 4.600%, and 4.900% senior notes due 2028, 2029, 2031, and 2034. |
| May 7, 2026 | earnings | Gilead reported Q1 2026 revenue of $7.0 billion and diluted EPS of $1.61, raising full-year guidance. |
| Aug 4, 2026 | Guidance: diluted_loss_per_share | -3.75 to -3.40 |
| Aug 4, 2026 | Guidance: non_gaap_diluted_loss_per_share | -0.65 to -0.30 |
| Aug 4, 2026 | Guidance: product_sales | 30100.00 to 30400.00 |
| Aug 6, 2026 | mda_quarterly | Gilead Sciences reported a net loss of $10.5 billion for the second quarter of 2026, primarily driven by $11.2 billion in acquired in-process research and development (IPR&D) expenses and a $1.75 billion impairment charge related to the discontinuation of the EVOKE-03 study for Trodelvy in non-small cell lung cancer. Despite these charges, total revenue grew 10% year-over-year to $7.8 billion, fueled by strong performance in the HIV portfolio, where Biktarvy sales rose 7% and Descovy sales increased 48%. The company’s aggressive expansion strategy included the acquisitions of Arcellx ($6.4 billion), Tubulis ($3.2 billion), and Ouro Medicines ($1.9 billion), which significantly impacted cash reserves and operating expenses. Gilead’s cash and cash equivalents declined to $3.2 billion as of June 30, 2026, down from $7.6 billion at year-end 2025, largely due to these acquisitions and the liquidation of the marketable debt securities portfolio. Legal risks remain a focal point for analysts, particularly regarding ongoing antitrust litigation and product liability claims involving HIV medications. While the company recently secured a favorable ruling in California state court regarding Viread and Truvada, other litigation, including Phase II antitrust claims and qui tam lawsuits, continues to pose potential financial exposure. |
| May 7, 2026 | mda_quarterly | Gilead Sciences reported a 4% increase in total revenues to $6.96 billion and a 54% rise in net income to $2.02 billion for the first quarter of 2026. This growth was primarily driven by strong HIV product sales, with Biktarvy increasing 7% to $3.36 billion and Descovy up 38% to $807 million, alongside a 37% surge in oncology drug Trodelvy sales to $402 million. Conversely, Veklury sales declined 52% to $144 million due to fewer COVID-19 hospitalizations, and Cell Therapy products (Tecartus, Yescarta) saw a 12% decrease amidst competitive headwinds. Product gross margin improved to 79.2%. Post-quarter, Gilead significantly expanded its pipeline through acquisitions, including Arcellx for anito-cel (multiple myeloma, BLA accepted), Tubulis for next-generation antibody-drug conjugates, and Ouro Medicines for OM336 (autoimmune T cell engager). These deals are projected to result in approximately $11.5 billion in acquired in-process research and development expenses in Q2 2026, leading to an expected net loss for both the second quarter and the full year. Operating cash flow increased 45% to $2.54 billion, and $2.75 billion in senior unsecured notes were repaid, though a new $1.1 billion term loan was secured. The company faces ongoing material financial risks from significant litigation, including antitrust lawsuits concerning HIV drugs and product liability claims related to older HIV treatments. |
Source: SEC EDGAR filing text and events; period Aug 4, 2026; filed Aug 4, 2026.
GILD company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.